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Abstract
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There is ample empirical evidence to support the notion that the biological impacts of estrogen
extend beyond the gonads to other bodily systems, including the brain and behavior. Converging
preclinical findings have indicated a neuroprotective role for estrogen in a variety of experimental
models of cognitive function and brain insult. However, the surprising null or even detrimental
findings of several large clinical trials evaluating the ability of estrogen-containing hormone
treatments to protect against age-related brain changes and insults, including cognitive aging and
brain injury, led to hesitation by both clinicians and patients in the use of exogenous estrogenic
treatments for nervous system outcomes. That estrogen-containing therapies are used by tens of
millions of women for a variety of health-related applications across the lifespan has made
identifying conditions under which benefits with estrogen treatment will be realized an important
public health issue. Here we provide a summary of the biological actions of estrogen and estrogencontaining formulations in the context of aging, cognition, stroke, and traumatic brain injury. We
have devoted special attention to highlighting the notion that estrogen appears to be a conditional
neuroprotectant whose efficacy is modulated by several interacting factors. By developing criteria
standards for desired beneficial peripheral and neuroprotective outcomes among unique patient
populations, we can optimize estrogen treatments for attenuating the consequences of, and perhaps
even preventing, cognitive aging and brain injury.
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1. Introduction: the role of estrogen beyond the gonads

Author Manuscript

Our current understanding of the biological role of the sex hormone estrogen and more
broadly, the field of women’s health, has its origins in the avian testis. Indeed, in 1849, the
physiologist Arnold Adolf Berthold reported on his findings regarding the anatomical and
behavioral consequences of testicular removal and transplantation in roosters (Berthold,
1849). In an elegantly designed experiment, Berthold subjected cockerels to full or partial
testicular removal. Among animals in which both testes were excised, physiology and
behavior was markedly altered in that “they were not aggressive, they fought other cockerels
rarely and in a half-hearted manner, and developed the monotone voice of the capon”. Yet, in
birds that had only one testis removed or in castrated birds who received testicular
transplantation, he noted that behavior remained indiscernible from that of a normal rooster,
with these birds still crowing, fighting, and displaying the “usual reactions to hens”. Given
that the transplanted testes did not always re-establish nerve connections within the rooster,
Berthold attributed these findings to “some productive function of the testes. . . by their
action on the blood stream, and then by corresponding reaction of the blood on the entire
organism, of which, it is true, the nervous system represents a considerable part.” Thus,
whether Berthold realized the impact of his discovery or not, this experiment provided some
of the first empirical support for the influence of sex hormones on the body and brain.

Author Manuscript
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Characterizing the physiological impacts of estrogen is as important today as it was in
Berthold’s era. Nearly half of the global population is female, and sex-specific shifts in
endogenous hormone levels related to cyclicity, pregnancy, and menopause are associated
with differences in cognitive performance as well as altered risk for, and outcome from,
neurological insults (Kimura, 2002; Kittner et al., 1996; Lisabeth and Bushnell, 2012;
Workman et al., 2012). Further, today tens of millions of women use estrogen-containing
treatments for many reasons ranging from menstrual cycle regulation to contraception to the
amelioration of symptoms associated with the menopausal transition (Hersh et al., 2004;
Jones et al., 2012). Although numerous reports note a multitude of beneficial
neuroprotective effects of estrogens (reviewed in Acosta et al., 2013; Arevalo et al., 2015;
Brown, 2009; Luine, 2014; Simpkins and Singh, 2008), the use of estrogenic compounds is
controversial. Indeed, the known increased risk of stroke associated with oral contraceptive
(OC) use coupled with the surprising null or even detrimental findings of the large, doubleblind, placebo-controlled Women's Health Initiative (WHI) clinical trial regarding the risk
for adverse outcomes among post-menopausal women taking hormone therapy (HT) led to
hesitation by both clinicians and patients in the use of exogenous estrogen-containing
treatments for brain-related outcomes (Kittner et al., 1996; Manson et al., 2013). Thus, there
is a pressing medical need to understand the conditions under which estrogens exert
neuroprotection.
Here, we review the literature regarding the nature of neuroprotection by estrogen and
estrogen-containing compounds among females. We limited this discussion to studies in
which human participants, rodent subjects, or in vitro cultures were utilized to assess the
effects of ‘estrogen’ within the context of cognition, stroke, and traumatic brain injury
(TBI). Our strategy for selection of published articles for citation in the current review is
defined by the inclusion of studies in which a finding was first demonstrated, as well as
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seminal papers describing key caveats within a given field of research. In areas of research
where the number of published studies is limited (for example, the cognitive impacts of
estrone; E1), we made efforts to include all work conducted. Whenever possible, references
included are primary research articles although we have also directed readers to several
thorough and key reviews exhaustively addressing topics beyond the scope of the current
discussion. For instance, neuroprotective actions of estrogens, and the complex mechanisms
underlying these effects, have been documented in several domains of neurological function,
injury, and disease (Chakrabarti et al., 2014), such as the experimental autoimmune
encephalomyelitis model of multiple sclerosis (Offner and Polanczyk, 2006), spinal cord
injury (Elkabes and Nicot, 2014) and Parkinson's Disease (Smith and Dahodwala, 2014), to
name just a few. The beneficial effects of estrogens in these domains are noteworthy and we
direct the reader to several key reviews on each of these important subjects.

Author Manuscript

As well, the majority of exogenous estrogen-containing therapies given to women also
include a progestin. Progestins have known actions in the nervous system, many of which
can be beneficial (Brinton et al., 2008). However, mounting evidence suggests that the
addition of a progestin may in fact attenuate, obviate, or even reverse the beneficial actions
of estrogens when administered together (Acosta et al., 2013). Indeed, many factors likely
influence the impact of estrogen + progestin combination HTs including the type of
progestin administered (natural progesterone versus synthetic versions), the age of the
organism at time of treatment, and the duration between hormone depletion and subsequent
treatment (Singh and Su, 2013). A detailed discussion of the neuroactive effects of
progesterone, either alone or in combination with estrogen, is beyond the scope of this
review and has been extensively discussed elsewhere. The authors direct interested readers
to several excellent reviews on this subject (Deutsch et al., 2013; Wei and Xiao, 2013).
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Of note, in many previously published reports, the term estrogen has been used
indiscriminately and interchangeably to refer to both the large hormonal group or a specific
molecule. As highlighted by Blaustein (2008), the importance of precision in hormone
nomenclature is critical. For instance, until recently, the vast majority of studies assessing
the neuroprotective effects of estrogen in animals utilized 17 beta-estradiol (17βE2). Yet, for
the woman, a wide variety of hormone treatment options exist ranging from ethinyl
estradiol-based OCs to 17βE2-based vaginal creams to Premarin®-based menopausal HTs
(conjugated equine estrogens; CEE). As will be discussed in detail below, not all estrogens
impart the same neurobiological effects and many of these estrogens and estrogencontaining compounds have yet to be comprehensively evaluated for their unique
neurobiological actions. Thus, for the purposes of this review, when the term estrogen is
used, we refer to the broad class of natural and synthetic estrogen-like molecules that have
estrogenic activity at the various estrogen receptors. As well, whenever possible, when
referencing work in which exogenous estrogen treatment is administered, the specific
estrogen used in each study cited will be listed.
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2. The estrogen molecule, its receptors, and its biological actions in the
body and brain
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Steroid hormones are synthesized from cholesterol through a variety of chemical reactions
and can exert important physiological effects throughout the lifespan. 17βE2 is the most
potent naturally-circulating estrogen, followed by E1 and estriol (E3), in order of receptor
affinity (Kuhl, 2005; Sitruk-Ware, 2002). These and other hormones play crucial roles in the
modulation of central nervous system (CNS) substrates and the behaviors they regulate.
Indeed, endogenous hormones can have organizational physiological effects, operationally
defined as permanent changes in tissue which occur early in life (either during prenatal
development or in the initial days of the post-natal period); these organizational effects
cannot be reversed by hormone depletion (Arnold, 2009). As well, later in life, activational
effects of endogenous sex steroids and/or exogenous hormone administration can transiently
impact the structure and function of these organized neural substrates and pathways. It has
been suggested that both organizational and activational hormone actions account for the
well-documented sex differences in cognitive outcomes and sex-specific risks for, and
consequences of, diseased/injured brain states (Kimura, 2002; Manwani and McCullough,
2011). Although hormone levels can vary greatly across the menstrual cycle and some of
these variations have been associated with cycle stage-specific alterations in cognitive
performance and damage following brain injury, the ratio of circulating 17βE2:E1 is
generally considered to be 1:1 during the reproductive years of adulthood (Rannevik et al.,
1995). A notable exception to this is during pregnancy, in which E3 produced by the
placenta is the predominant circulating estrogen; levels decline rapidly in the post-partum
period (Neves-e-Castro, 1975). As women age, they experience menopause, a transition
from reproductive capability to reproductive senescence (Timiras et al., 1995). The
menopausal transition, typically occurring during the fifth decade of life, is characterized by
depleted ovarian follicles, declines in naturally circulating levels of sex hormones, such as
estrogens and progesterone, and a dysregulation of gonadotropin feedback loops marked by
increasing levels of follicular stimulating hormone and luteinizing hormone (Rannevik et al.,
1995). During this time, the ratio of circulating estrogen levels shifts such that E1 is the
principle circulating estrogen (Rannevik et al., 1995). As a result of these changing hormone
levels, menopause is accompanied by hot flashes, urogenital atrophy, cognitive decline
(specifically learning and memory), changes in risk for neurodegenerative diseases,
worsened outcomes following brain trauma, and other symptoms that reduce quality of life
(Freedman, 2002; Sherwin and Henry, 2008). These consequences of the menopausal
transition become important when considering that life expectancy has increased over the
past century, but the age of spontaneous menopause has not changed (Hawkes, 2003). This
means that women now spend a larger proportion of life in this post-menopausal,
hypoestrogenic state associated with numerous negative physiological and neurological
consequences. As well, the size of the aging female population is growing. By the year
2050, 90 million people are projected to be over 65 years of age (US Census, 2008). Given
that women tend to outlive men, over half of this large aging population will be women.
Thus, understanding the physiological impacts of female sex hormones is, and will continue
to be, a crucial public health issue.
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Many of the diverse biological effects of estrogen are mediated by ligand interactions with
two classical nuclear estrogen receptors (ER), ER-alpha (ERα) and ER-beta (ERβ). Both
ERs are members of the nuclear receptor superfamily (Peterson, 2000) but they differ in
their chromosomal localizations and ligand-binding domains (Gustafsson, 1999). Discovered
in uterine tissue (Jensen and Jacobson, 1962; Toft and Gorski, 1966) and cloned in 1986
(Greene et al., 1986), ERα was the first nuclear ER that demonstrated binding specificity for
17βE2 and was thought to be the sole ER with which all estrogens interacted. However, 10
years later, the discovery of a second nuclear ER in a cDNA library from rat prostate, ERβ,
added clarity, and perhaps more complexity, to our understanding of the pharmacology and
physiology of ER function (Kuiper et al., 1996). Currently, six ERβ splice variants have
been reported in the brain and other tissues. Intriguingly, the ERβ1 isoform exhibits a
neuroprotective role, functioning as a tumor suppressor, while the ERb2 isoform appears to
function in a dominant negative role to initiate oncogenesis (Böttner et al., 2014; Dey et al.,
2015; Handa et al., 2012). Both ERα and ERβ regulate the physiological actions of
estrogens primarily through the classical genomic signaling pathways, through which
binding of an estrogenic ligand to ERα or ERβ in the cytoplasm promotes translocation of
the ligand-receptor complex to the nucleus to serve as a transcription factor via binding to
estrogen response elements (EREs) at gene promoters. Studies over the past decade have
also revealed important physiological roles for another ER, G-protein coupled ER 1
(GPER1; previously known as GPR30), in the brain and periphery. In contrast to ERα and
ERβ, ligand binding to GPER1 occurs exclusively at the membrane and mediates several of
the rapid, nongenomic signaling actions of estrogens (Prossnitz and Barton, 2014).
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The pleiotropic actions of estrogens are amplified by the complex and diverse pattern of ER
distribution throughout the brain and periphery. Traditionally, ERs have been associated with
organs and tissues such as the uterus, ovaries, breast, hypothalamus, and pituitary and
participate in the classical reproductive functions. As well, numerous nonreproductive
functions for ERs have been identified in several other bodily tissues and organ systems
including brain, cardiovascular tissue, bone, immune cells, and liver (Kuiper et al., 1997).
Within the brain, ER subtypes are found in cognitive brain regions associated with learning
and memory, such as the amygdala, cerebral cortex, hippocampus, and basal forebrain
(Shughrue et al., 1997; Shughrue et al., 2000). ERs have also been identified in nearly all
cell types found in the CNS, including neurons, astrocytes, microglia, oligodendrocytes,
endothelial cells, and vascular smooth muscle cells. The physiological actions of each ER
are not mutually exclusive, as converging data suggest the existence of both distinct and
overlapping complex biological roles for each receptor subtype. Indeed, the physiological
mechanisms with which endogenous and/or exogenous estrogens can impart their effects are
diverse as estrogens participate in numerous modes of signal transduction. That estrogens
can be synthesized de novo or via the action of aromatase in distinct brain regions further
exemplifies the complexity of estrogenic signaling cascades (Li et al., 2014). The modes of
ER signaling have significantly expanded beyond the traditional view of ERα and ERβ as
transcription factors to include: rapid effects at the membrane on signal transduction
pathways ligand, ligand-independent signaling, and receptor binding to non-traditional
ligands (Deroo and Korach, 2006). Specific mechanisms of action for ERs in stroke, TBI,
and cognition will be addressed later in this review (see Section 4).
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3. Use of rodent models to assess estrogenic actions in the nervous
system
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Within the context of aging and age-related hormone depletion, given the many parallels
between humans and this animal model, from the basic science perspective the middle-aged,
ovariectomized (Ovx) rodent is the gold standard. For instance, the effects of aging among
women and rodents for a variety of insults including cognitive aging and brain injury are
homologous. Indeed, cognitive aging occurs spontaneously in both species (Berchtold and
Cotman, 2009) and stroke or stroke model neuropathology is similar in both humans and
rodents (Durukan and Tatlisumak, 2007). Further, the physiological and cognitive
consequences following surgical hormone depletion are also similar in both species. For
instance, following oophorectomy in women, in which the ovaries are excised, circulating
levels of sex hormones including 17βE2 and testosterone decline (Laughlin et al., 2000).
Similarly, following surgical ovary-removal in rats, circulating estrogens and progesterone
fall to low levels (Wise and Ratner, 1980). In both species, the sudden loss of ovarian
hormones is also associated with memory impairments (Acosta et al., 2013; Henderson and
Sherwin, 2007; Rocca et al., 2011). Further, stroke risk is higher among oophorectomized
women who underwent surgical menopause prior to 40 years of age relative to women who
underwent natural menopause during their early fifties (Baba et al., 2010), and stroke
outcome is poorer among Ovx rodents compared to intact controls, at least in young adult
animals (Leon et al., 2012). It is noteworthy that the Ovx methodological approach
dramatically reduces levels of numerous other sex hormones including progesterone (Wise
and Ratner, 1980), creating a background of minimal estrogen and progesterone hormone
levels with which to assess the unique impacts of hormone loss or treatment. However, Ovx
also initiates dramatic shifts in circulating gonadotropin levels (Wise and Ratner, 1980), an
important consideration in the interpretation of findings using this model.

Author Manuscript

Despite the similarity in ovarian hormone profiles following surgical ovary removal in
women and rats, an important limitation of this model is that most women do not undergo
surgically-induced menopause. Indeed, the majority of women experience transitional
menopause, in which follicles deplete and hormone levels change over many years, while
only small portion of women experience oophorectomy (Timiras et al., 1995). This begs the
question, why do we not use the intact aging female rat as a model of human menopause?
The answer to this stems from differences in the mechanisms and the trajectory of
spontaneous, transitional reproductive senescence in the two species. In women, the
depletion of the ovarian follicles ultimately induces reproductive senescence (Neal-Perry et
al., 2010). Conversely, in female rodents, the ovaries remain capable of reproduction given
that transfer of an ovary from an aged donor rat to a young female recipient can still result in
the support of normal cyclicity and the maintenance of viable pregnancies (Peng and Huang,
1972). Instead, the proposed mechanism of female rodent reproductive senescence is
dysregulation of the hypothalamic-pituitary-gonadal axis to respond to 17βE2 positive
feedback. Indeed, Selmar Aschheim's 1964 seminal findings revealed that transplant of a
young adult ovary into an aged rats failed to restore cyclicity (Neal-Perry et al., 2010).
Similarly, transplant of hypothalamic nuclei from an aged rat into a young recipient
disrupted normal cyclicity in these younger animals (Peng and Huang, 1972). This age-
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related hypothalamic dysregulation results in highly irregular cycles consisting of either
constant estrus or persistent diestrus states, characterized by moderate levels of 17βE2 and
high levels of progesterone, respectively (Lu et al., 1979; Wise and Ratner, 1980). Therefore,
although evidence suggests that alterations in hypothalamic-pituitary-gonadal axis feedback
mechanisms are early mediators of the menopausal transition in both women and rodents
(Neal-Perry et al., 2010), the fundamental differences in follicular content and ovarian
functional capacity during aging limit the utility of the ovary-intact aging rodent in studies
investigating the aging process. However, new rodent models of transitional human
menopause have been recently developed that selectively deplete ovarian follicles (Mayer et
al., 2005) and have important implications for the field of women's health (see Section 7.2).

4. Mechanisms of estrogen neuroprotection
Author Manuscript
Author Manuscript

Estrogens have been shown to impact a number of distinct cell types, neuronal signaling
cascades, and nervous system substrates associated with cognitive aging, injury, and disease
(Prokai and Simpkins, 2007). Thus the mechanism behind estrogen's neuro-protective effects
is most likely a multifactorial combination of diverse neurobiological and signaling impacts.
As well, the source of estrogen may play an important role in neuroactivity and protection
from injury as estrogens are derived not only from ovary in the periphery but also can be
synthesized from cholesterol de novo or via the action of aromatase in various brain regions,
such as the hippocampus, and by several neural cell types, including neurons and astrocytes
(Li et al., 2014). It has been hypothesized that much of estrogen's protective actions in the
brain following injury may be due to not to peripherally-derived estrogens but to estrogens
synthesized within the CNS (Fester and Rune, 2014; Zhang et al., 2014), and this hypothesis
has been reviewed elsewhere (Arevalo et al., 2015). The major neuroactive effects of
estrogens are discussed here.
4.1. Cerebral microvasculature and blood–brain barrier

Author Manuscript

Compromised cerebral microvascular function impairs the integrity of the blood–brain
barrier (BBB). The cerebral microvasculature, and by extension, the BBB, is a major target
of estrogen action. ERα, ERβ, and GPER1 are expressed on brain endothelial cells, although
most of the physiological activity of 17βE2 is mediated through ERα (Duckles and Krause,
2011; Spary et al., 2009). Estrogens exert multiple protective actions at the
cerebrovasculature by increasing vasodilation, decreasing vascular inflammation, and
enhancing mitochondrial function. Acting through both genomic and non-genomic
mechanisms, 17βE2 also increases expression of endothelial nitric oxide synthase (eNOS)
which promotes increased vasodilation through enhanced nitric oxide availability in cerebral
tissues (Duckles and Krause, 2011).
The protective actions of 17βE2 in brain endothelial cells is extended to the BBB, the
dynamic interface that permits the passage of small molecules and limits entry of immune
cells and larger inflammatory molecules into the brain parenchyma. The permeability of the
BBB may be modulated through both ERα and ERβ (Bake and Sohrabji, 2004; Brown et
al., 2010; Cipolla et al., 2009). 17βE2 also plays an important role in mediating
leukocyteendothelial interations. It decreases messenger ribonucleic acid (mRNA)
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expression of the proinflammatory endothelial molecules e-selectin, ICAM-1, and VCAM-1
(Nakagami et al., 2010). Further, tight junction (TJ) proteins are critical for maintaining the
structure and integrity of the vascular endothelial membrane in capillaries but play a less
important role at postcapillary venules (Bechmann et al., 2007). The TJ proteins occludin
and claudin-5 are also regulated by 17βE2 at the mRNA and protein level (Bake et al., 2009;
Burek et al., 2010).
4.2. Mitochondrial function
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several lines of evidence support a potential role of mitochondria in the neuroprotective
effects of estrogens (Simpkins and Dykens, 2008). Long ago, estrogen was shown to bind to
components of the mitochondria, including the F0/F1 ATPase (Zheng and Ramirez, 1999a,b)
and more recently, we have shown ER localization to the mitochondria (Yang et al., 2004).
Estrogens also influence anti-apoptotic proteins (Nilsen and Brinton, 2003; Pike, 1999;
Singer et al., 1998; Wise et al., 2000; Yang et al., 2004; Zhao et al., 2004), which act on
mitochondria such that they increase the production of adenosine triphosphate (ATP) under
conditions of cellular stress (Wang et al., 2001, 2003a, 2006). With inhibition of ATP
production by 3-nitropropionic acid (3NPA), a succinate dehydrogenase inhibitor that
uncouples oxidative phosphorylation, estrogens reduce ATP decline. Similarly, H2O2 caused
a dose- and time-dependent decline in ATP production (Wang et al., 2003b, 2006) by
compromising mitochondrial oxidative phosphorylation. 17βE2 ameliorated the H2O2induced decline in cellular ATP (Wang et al., 2003b, 2006). More recently, we assessed the
effects of estrogens on the inhibition of mitochondrial function induced by β-amyloid
oligomers (Sarkar et al., 2015). We demonstrated that oligomeric β-amyloid caused a fission
of mitochondria, slowed their movement, and reduced oxidative phosphorylation; all of
these effects of oligomeric β-amyloid were ameliorated by 17βE2. Under glutamate
stimulation, estrogens enhance Ca2+ flux into cells (Nilsen et al., 2002; Zhao et al., 2004),
an effect that may be involved in estrogen's ability to increase memory function through an
N-methyl-D-aspartate (NMDA) receptor-mediated mechanism (Diaz Brinton, 2001; Foy et
al., 1999). Estrogens also potentiate Ca2+ influx through L-type Ca2+ channels (Sarkar et al.,
2008). However at high glutamate stimulation, estrogens reduce mitochondrial influx of
Ca2+ (Nilsen and Brinton, 2003; Nilsen et al., 2002; Wang et al., 2006).
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Estrogens also protect mitochondria Ca2+ from other stressors. 3NPA caused a rapid and
profound increase in cytosolic Ca2+ concentrations (Wang et al., 2001). Estrogens reduced
the influx of Ca2+ into the cytosol and mitochondria as a result of 3NPA treatment.
Similarly, cytosolic and mitochondrial Ca2+ levels were reduced by 17βE2 when H2O2 was
used as a pro-oxidant (Wang et al., 2006). Since sustained increases in mitochondrial Ca2+
impair oxidative phosphorylation, these observations indicate that the Ca2+ modulating
effects of estrogens protects ATP production, and as a result, neuronal viability. The role of
estrogenic mitochondrial actions in neuroprotection can be determined by the correlation
between the potency of compounds in assays of mitoprotection and neuroprotection. A
strong correlation between these two parameters supports the role of mitochondria in
neuroprotection. We tested the correlation between the neuroprotective activity of estrogens
and Δψm collapse induced by Ca2+ loading in a neuronal cell line. Ten estrogen analogs
with neuroprotective potency (ED50) of 20 nM to 8.6 μM were compared (Dykens, 1995).
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The correlation between ED50 values for neuroprotection and the ED50 values for Ca2+induced Δψm collapse were highly correlated (r2 = 0.73, Spearman r = −0.9387, p < 0.0001)
(Dykens et al., 2003), suggesting a strong relationship between these two parameters.
4.3. Anti-inflammatory actions

Author Manuscript

The neuroprotective and anti-inflammatory actions of estrogens in early ischemic stroke and
TBI are not mutually exclusive. The pleiotropic effects of estrogens and ERs across multiple
cell types within the brain makes it difficult to dissociate these mechanisms from each other.
Nevertheless, it is clear that physiological concentrations of 17βE2 exhibit dramatic antiinflammatory activity in the CNS when administered to young mice. Whether the antiinflammatory effects of 17βE2 persist following reproductive senescence (in rodents) or
menopause (in humans) is under intense investigation. The majority of studies suggest that
these effects do not persist in older female rodents (Leon et al., 2012; Sohrabji et al., 2013b;
Strom et al., 2011). In addition to the loss of the anti-inflammatory properties of 17βE2 in
young, Ovx mice, recent studies strongly suggest that the anti-inflammatory effects of
17βE2 are lost during a period of prolonged hypoestrogenicity in middle-aged (Suzuki et al.,
2007a), or reproductively senescent (Selvamani and Sohrabji, 2010a; Sohrabji et al., 2013a),
mice. 17βE2 also suppresses a systemic post-stroke immunosuppression phenotype in
animal models that closely mimics a peripheral immunosuppressive phenotype seen in
human patients (Ritzel et al., 2013; Zhang et al., 2010).
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Several excellent reviews address cell type-specific anti-inflammatory mechanisms of 17βE2
in microglia (Habib and Beyer, 2015; Vegeto et al., 2008), astrocytes (Acaz-Fonseca et al.,
2014), endothelial cells (Sohrabji et al., 2013a), and oligodendrocytes (Arevalo et al., 2010)
during neurological injury. In young and middle-aged preclinical animal models of stroke,
17βE2 inhibits the activation of the pro-inflammatory transcription factor, nuclear factor-κβ,
which induces transcription of numerous cytokines such as tumor necrosis factor-α (TNFα),
chemokine ligand 2 (CCL2), interleukin-6 (Vegeto et al., 2008). In contrast to its effects on
eNOS in the brain cerebral microvasculature, 17βE2 also decreases expression of inducible
NOS (iNOS), which produces nitric oxide as part of the innate inflammatory response
(Garry et al., 2015). Some of the anti-inflammatory actions of 17βE2 in ischemic stroke are
derived, in part, through interations with iNOS. In the permanent (pMCAO) middle cerebral
artery occlusion (MCAO) model of ischemic stroke, Ovx iNOS null mice exhibited smaller
infarct volumes than their wild type (WT) counterparts (Brown et al., 2008) but Ovx mice
were afforded no additional protection with 17βE2 replacement (Brown et al., 2008; Park et
al., 2006). More recent studies suggest that 17βE2 administration prior to transient MCAO
(tMCAO) suppresses activation of the inflammasome, a multiprotein intracellular complex
that coordinates the innate immune response, in male mice (Slowik and Beyer, 2015).
4.4. Free-radical scavenging
Estrogens exert anti-oxidant effects (Ayres et al., 1996; Miller et al., 1996; Mooradian, 1993;
Romer et al., 1997a,b; Sawada et al., 1998; Tang et al., 1996) but are comparatively poor
scavengers of reactive oxygen species (ROS). For neurons exposed to H2O2, 17βE2 is
ineffective in reducing cellular ROS levels as measured by general ROS dyes. However,
17βE2 is effective in preventing the production of ROS induced by 3NPA treatment (Wang
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et al., 2006). The observation that estrogens are potent in preventing ROS production led us
to investigate their role in inhibition of lipid peroxidation. In neuroprotection assays in vitro,
we showed that estrogens interact with the abundant aqueous soluble anti-oxidant,
glutathione (Green et al., 1998; Gridley et al., 1998). Also since estrogens have a log P of
about 3, they reside in the membrane component of cells (Liang et al., 2001), where they
could prevent oxidation of phospholipids. Estrogens then may interrupt lipid peroxidation
chain reactions using a major source of cellular reducing potential, such as glutathione or
nicotinamide adenine dinucleotide phosphate (NADPH). We described estrogen conversion
to a quinol product that was able to be reduced back to the parent estrogen in the presence of
NADPH (Prokai et al., 2003a,b).
4.5. Synaptic and structural plasticity
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Estrogen has known impacts on measures of plasticity within the CNS and this may
represent an important mechanism by which estrogens can impact cognitive function. For
instance, dendritic spine morphology and number are known to change following learning or
long-term potentiation (LTP; Bliss et al., 2007); Woolley and colleagues first established that
shifts in endogenous estrogen levels across the estrous cycle impacted dendritic architecture
complexity in the cornu ammonis 1 (CA1) region of the hippocampus (Woolley et al., 1990).
This same group later showed that hormone loss reduced spine number, and subsequent
treatment with 17βE2 reversed this loss (Woolley and McEwen, 1992), an effect that was
mediated by an NMDA receptor-dependent mechanism (Woolley and McEwen, 1994;
Woolley et al., 1997), further supporting the ability of estrogen to modify hippocampal
structure. As well, enhanced LTP has been noted in cycling females during the proestrous
stage, when estrogen levels are high (Good et al., 1999; Warren et al., 1995), and chronic
17βE2 treatment attenuates the disruptive effect of hormone depletion on long-term
depression (Day and Good, 2005). Further, estrogen appears to modulate LTP through
interaction with ERβ (Liu et al., 2008), which are localized within hippocampal axons,
dendrites, and dendritic spines (Milner et al., 2001, 2005). More specifically, Liu et al.
(2008) demonstrated that there were significant increases among synaptic plasticity marker
proteins PSD-95 and GluR1 in Ovx wild type animals that received the ERβ agonist,
WAY-200070. Interestingly, these changes were not shown among Ovx WT mice that
received the ERα agonist nor in ERβ knockout (KO) mice. As well, hippocampal slices
treated with WAY-200070 enhanced LTP when slices were from WT but not ERβ KO,
female mice.
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In addition to modifying synaptic architecture within a set of neurons, it appears that
estrogen can modify structural plasticity to influence brain function. Neurogenesis, the
process of creating new neurons, is indispensable in early brain development and to adult
brain function. Previously, neurogenic activity was thought to be limited to early critical
periods of neuronal development and 17βE2 appears to have a role in this process. Indeed,
17βE2 promotes neuritogenesis in developing hippocampal neurons via a GPER-dependent
mediated mechanism (Ruiz-Palmero et al., 2013). However, numerous laboratories have
clearly demonstrated that neurogenesis also occurs in the subventricular zone (SVZ) and
dentate gyrus (DG) in rodent and human adult brain (reviewed in Aimone et al., 2014). In
the adult brain, sex hormones have been found to influence the number of new neurons
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present in the hippocampal formation (Gould, 2007). Seminal findings from the Gould
laboratory noted dramatic fluctuations in proliferation of progenitor cells with changes in
endogenous estrogen levels across the cycle (Tanapat et al., 1999). Hormone depletion
significantly reduces proliferating neuron number and 17βE2 treatment can reverse this if
administered near the time of Ovx; this appears to occur through both genomic ER subtypes
(Barha et al., 2009b; Ormerod et al., 2003; Suzuki et al., 2007b; Tanapat et al., 2005).
4.6. Impacts on the cholinergic neurotransmitter system
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Estrogens may alter cognitive outcomes by their actions on distinct neurotransmitter systems
known to be involved with cognition. The basal forebrain cholinergic system is important for
learning and memory and is susceptible to age-related changes (for review, see Gibbs, 2010).
For example, in aged female rats with working memory impairments, less choline
acetyltransferase (ChAT) protein activity was found in the basal forebrain, relative to
younger counterparts (Luine and Hearns, 1990), suggesting that lower levels of ChAT
activity are associated with worse memory performance during aging. 17βE2 seems to
beneficially impact the basal forebrain cholinergic system, as well as cognitive performance.
In adult Ovx rats, 17βE2 treatment increased ChAT protein activity and ChAT
immunoreactive cell counts in distinct basal forebrain subregions (Gibbs, 1997). Further,
evidence from Gibbs’ laboratory suggests that not only did 17βE2 enhance memory
performance but that the beneficial effects of 17βE2 treatment on cognition require a
functioning basal forebrain cholinergic system. Indeed, 17βE2 was ineffective at improving
cognition in animals with basal forebrain lesions, and enhanced memory only in nonlesion
controls (Gibbs, 2002, 2007). Cholinergic projections to hippocampus are also involved with
the memory enhancing effects of 17βE2 (Fader et al., 1998, 1999; Packard, 1998). In
addition to 17βE2, other estrogenic formulations are known to impact the cholinergic
system. Indeed, CEE treatment in middle-aged Ovx rats increased basal forebrain ChATimmunoreactive neuron counts and concomitantly aided spatial memory and retention
(Acosta et al., 2009b). Yet, interestingly, the primary circulating estrogen following CEE
treatment, E1, which impaired memory performance, also failed to impact basal forebrain
ChAT-positive cell counts (Engler-Chiurazzi et al., 2012). Thus, these findings suggest that
the basal forebrain cholinergic system may be a crucial component of the cognitive
neuroprotection afforded by some, but not all, estrogens.
4.7. Cellular maintenance and survival

Author Manuscript

Neurotrophins may be one mechanism of estrogen-induced neuroprotection or mnemonic
changes. Survival and maintenance of neurons are dependent upon neurotrophins, including
nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF; Davies, 1996;
Granholm, 2000). Age-related neurotrophin changes have been reported in animal models,
and NGF and BDNF have been associated with cognitive function (Bimonte et al., 2003;
Granholm, 2000; Hall et al., 2000; Kesslak et al., 1998). 17βE2 treatment significantly
impacts neurotrophin systems in young and aged Ovx rats, increasing neurotrophin and its
receptor mRNA levels in basal forebrain, frontal cortex, and hippocampus (McMillan et al.,
1996; Pan et al., 1999; Singh et al., 1995; Sohrabji et al., 1995) as well as elevating NGF and
BDNF protein levels in cognitive brain regions (Bimonte-Nelson et al., 2004a,b). Moreover,
there is mounting evidence from the Sohrabji group that estrogen imparts neuroprotective
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action via interations with insulin-like growth factor (IGF) receptor (Sohrabji and Williams,
2013). Indeed, in young animals, blockade of IGF receptors obviates the protective actions
of 17βE2 against endothelin-1 (ET-1) induced stroke damage (Selvamani and Sohrabji,
2010b). Interestingly, it appears that protective actions of IGF are dependent on an estrogen
rich hormonal milieu as among aged animals, IGF was only effective at reducing infarct
volume in Ovx animals that had been treated with 17βE2, but not in Vehicle treated animals.
As well, it has been hypothesized that both estrogen and microglia-derived IGF act
synergistically to promote cellular health in the context of the injured brain (Sohrabji and
Williams, 2013).
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In addition to modulating the growth factor system, 17βE2 is also known to modulate cell
death cascades (Alkayed et al., 2001; Zhang and Bhavnani, 2006). Apoptosis and necrosis
are the two primary mechanisms of neuronal cell death during neurological injury, although
it is likely that other cell death mechanisms including autophagy are equally important
(Gabryel et al., 2012). The anti-apoptotic effects of estrogens during ischemic stroke and
TBI are well characterized in preclinical animal models. Numerous laboratories have shown
that physiological concentrations of 17βE2 exert anti-apoptotic actions in the infarct
penumbra but not in the infarct core, demonstrating that 17βE2 protects against delayed cell
death but not immediate cell death in ischemic injury. Most apoptotic mechanisms
implicated in stroke and TBI are either caspase-dependent or caspase-independent. Early
studies showed that low levels of 17βE2 upregulate the cell survival factor bcl-2, an
upstream inhibitor of caspases, in ischemic injury (Alkayed et al., 2001; Dubal et al., 1999).
Data from several labs suggests that one anti-apoptotic mechanism utilized by 17βE2 is the
suppression of activated caspase-3 during cerebral ischemia (Dubal et al., 2006; Harms et
al., 2001; Jover et al., 2002; Rau et al., 2003; Soustiel et al., 2005). The specific pathways
leading to caspase-3 activation are complex. The actions of caspase-3, a prototypical effector
caspase, are regulated by the actions of two initiator caspases, caspase-8 and caspase-9.
Caspase-8 activation is a hallmark of the extrinsic death receptor-mediated pathway, while
caspase-9 activation is a hallmark of the intrinsic mitochondrial-cytochrome death pathway
(Budihardjo et al., 1999; Zhang et al., 2004). Studies from the McCullough laboratory have
implicated an important sex-specific mechanism for caspase-mediated effects of estrogens in
ischemic stroke. Interestingly, caspase-dependent cell death mechanisms predominate in
female mice while caspase-independent mechanisms are preferentially utilized in male mice
(Koellhoffer and McCullough, 2013; Liu et al., 2009).

5. Estrogen and cognitive neuroprotection
5.1. What is cognition and how is it assessed in the human versus the rodent?
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Cognition is an exceedingly large umbrella term used to describe the higher order neural
processing and behavioral output that occurs within an organism in response to a given
stimulus. Some of these responses may be simple, almost reflexive (such as the aversive
avoidance withdrawal), and can be tested with ease in multiple experimental models
spanning the entirety of the evolutionary totem pole. However, many responses are
exceptionally complex and require the coordinated efforts of several neural systems in order
to generate an appropriate behavioral output. Given the high degree of homology and
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translatability between the everyday memory demands and mnemonic processing of humans
and lower species, tests of learning and memory are commonly employed in preclinical
evaluations of hormone effects on cognition. The demonstration of learned content by an
organism is contingent upon a variety of factors including the perception of, and attention to,
the information/stimulus to be learned, the consolidation of this information from short-term
to long-term memory, and the eventual retrieval and recall of the necessary information
when required. Estrogens are known to impact multiple aspects of this complex mnemonic
system.
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A number of tests with a high degree of human translational validity are employed in
preclinical studies assessing learning and memory in rodents (Rodriguiz and Wetsel, 2006).
Tests assessing hippocampal-dependent spatial navigation memory, a form of declarative
memory that involves the ability to learn to utilize and remember distal landmarks that are
associated with obtaining a reward and/or avoiding an aversive stimulus within a complex
environment (Eichenbaum, 2000), are common in the field of rodent cognition. The ability
to accurately navigate through space is crucial for the survival of all organisms, and
performance on these tasks has been shown to be similar in both humans and rodents (for
example, see Mennenga et al., 2014). Many tests, such as the Morris water maze (MM),
assess hippocampal-dependent spatial reference memory (Morris et al., 1982), memory for
information that remains consistent across time (Olton, 1979). As well, the spatial working
memory system facilitates memory for information that changes across time, and must be
updated, manipulated, and kept in a readily available state (Baddeley, 2010; Jarrard et al.,
1984; Olton, 1979). In addition, tests of novelty recognition are often employed given their
relative ease of implementation and established use in the field (Ennaceur, 2010). Finally,
fear-mediated memory can be assessed through the use of painful stimuli associated with a
certain context, such as the active/passive avoidance, or contextual fear conditioning,
paradigms (Maren, 2001). Many of these mnemonic processes are known to decline with
increasing age and are impacted by estrogens in both species (Rodefer and Baxter, 2007),
making them useful for the evaluation of estrogen effects in an aging preclinical model.
5.2. Effects of endogenous estrogens on cognitive function
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Among humans, several lines of evidence support the impact of estrogen on cognition.
Pronounced and reliable sexual dimorphisms in cognitive performance on specific functional
domains established unique roles for the distinct sex hormones in cognition (reviewed in
Kimura, 2002). For instance, men exhibit a clear advantage in visuospatial memory whereas
women outperform men in tasks of verbal fluency and verbal memory (Bleecker et al., 1988;
Galea and Kimura, 1993; Vandenberg and Kuse, 1978). Interestingly, cognitive performance
among women is not static but fluctuates dramatically with changing levels of endogenous
estrogens. For instance, women experiencing their menses, when estrogen levels are low,
tend to display better performance on tasks typically associated with a male advantage
(Hampson, 1990). Similarly, peri- and post-menopausal women show impaired memory
scores, especially when compared to pre-menopausal women (Farrag et al., 2002; Greendale
et al., 2010), with abrupt hormone loss via surgical oophorectomy prior to the age of natural
menopause exacerbating cognitive decline (Nappi et al., 1999; Rocca et al., 2007). As well,
some, but not all, studies note an association between worse memory performance and lower
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circulating estrogen levels among aging women (Lebrun et al., 2005; Wolf and Kirschbaum,
2002; but see Almeida et al., 2005; Barrett-Connor and Goodman-Gruen, 1999; Henderson
et al., 2013). Thus, converging data suggest that endogenous hormones can impact
mnemonic function and indicate that low levels of circulating estrogens is not optimal for
cognition. Mirroring the results of experiments in humans, findings from the animal
literature also support the notion that estrogen impacts cognitive outcomes. Males
outperform females on tasks of spatial navigation memory (Luine and Rodriguez, 1994) and
fluctuations in endogenous circulating sex hormone levels among females may moderate this
effect. Some rodent studies have reported more accurate reference memory performance on
the MM among female animals in estrus (Warren and Juraska, 1997), a phase of the estrous
cycle when circulating 17βE2 levels tend to be low relative to other stages (Lerner et al.,
1990). Yet, enhanced reference memory performance has also been found during the
proestrous phase when circulating estrogen levels surge (Frick and Berger-Sweeney, 2001).
Still others have reported no alterations in working and reference memory performance
across any estrous cycle stage (Berry et al., 1997; Stackman et al., 1997). Further supporting
the notion of hormone-related changes in cognitive performance, age-related declines in
spatial memory tend to emerge between 12 and 18 months of age (Markowska, 1999) when
female rodents undergo the estropausal transition associated with increases in circulating
gonadotropins, declines in estrogen levels, and dysregulation of progesterone and androgens
(Lu et al., 1979). As is the case in women, surgical depletion of endogenous circulating sex
hormones via Ovx in the rodent is associated with impairments on cognitive outcomes when
compared to intact, cycling controls (Bimonte and Denenberg, 1999; Daniel et al., 1999;
Feng et al., 2004; Talboom et al., 2008; Wallace et al., 2006).
5.3. Cognitive effects of exogenous estrogen treatments
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Additional support for the beneficial effect of estrogen comes from findings of studies in
which exogenous estrogen administration appears to ameliorate the cognitive deficits
associated with hormone loss in both humans and rodents. In an elegantly designed study,
Sherwin (1988) noted maintained verbal memory scores among women who received 17βE2
HT following surgical removal of the ovaries while those women who received vehicle
following oophorectomy surgery showed declined performance across time. As well,
treatment of post-menopausal women with Alzheimer's Disease with transdermal 17βE2
improved performance on tasks of attention and verbal memory (Asthana et al., 1999). Other
findings, including case studies (Ohkura et al., 1995), non-randomized quasi-experimental
designs (Carlson and Sherwin, 1998) and small double-blind, placebo controlled studies
(Campbell and Whitehead, 1977), also support a protective role for the most commonlyprescribed estrogen-containing menopausal treatment, CEE. However, several notable
reports have found null or even detrimental cognitive effects following the administration of
HT. For instance, findings from the now controversial WHI Memory Study (WHIMS)
showed that CEE treatment yielded a non-significant increased incidence of probable
dementia and mild cognitive impairment in women 65 and over (Espeland et al., 2004;
Shumaker et al., 2004). Further, there was an elevated probable dementia risk, and no effect
on mild cognitive impairment, in women with an intact uterus and ovaries taking Prempro®
(CEE + medroxyprogesterone acetate (MPA); Shumaker et al., 2003). Thus, disagreement of
clinical findings regarding the neuroprotection afforded by estrogen-containing treatments

Prog Neurobiol. Author manuscript; available in PMC 2018 October 01.

Engler-Chiurazzi et al.

Page 15

Author Manuscript

has resulted in uncertainty among medical practitioners and patients regarding the
effectiveness of estrogen for protection against cognitive aging and dementia.
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17βE2 is the most commonly tested estrogen for cognition in the rodent, and a plethora of
evidence supports the notion that treatment with this estrogen enhances learning and
memory (Table 1). In young adult animals, studies assessing the effects of treatment with
17βE2 following Ovx note beneficial effects on tasks of novel object recognition and object
location memory (Gresack and Frick, 2004; Lewis et al., 2008; Luine et al., 2003), aversive
avoidance memory (Foster et al., 2003; Simpkins et al., 1997a; Singh et al., 1994), and
spatial working and reference memory (Bimonte and Denenberg, 1999; Daniel et al., 1997;
El-Bakri et al., 2004; Gibbs, 1999; Hruska and Dohanich, 2007; Luine and Rodriguez, 1994;
Talboom et al., 2008). Interestingly, the effects of exogenous administration of estrogens
seem to be modulated, at least in part, by the age of the animal at the time of treatment.
Indeed, converging data suggest that cognitive responsiveness to estrogen stimulation
declines with age (Foster et al., 2003; Gresack et al., 2007; Talboom et al., 2008). For
instance, the same dose of 17βE2 treatment that effectively enhanced performance on the
MM among 4 and 16 month old, Ovx rats was generally ineffective in 24 month olds
(Talboom et al., 2008). It is known that ER distribution changes with age in both aging
women and Ovx rats (Adams et al., 2002; Mehra et al., 2005; Waters et al., 2011;
Yamaguchi-Shima and Yuri, 2007) and it has been hypothesized that changes in ER ratios
during aging may account for this reduced receptivity to estrogen treatment (Foster, 2012).
However, some studies still report benefits of 17βE2 administration in aged rodents (Frick et
al., 2002; Markowska and Savonenko, 2002), suggesting that other factors may interact to
influence the realization of cognitive benefits with 17βE2 (see Section 7).
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One strategy to optimize estrogenic HTs for cognitive outcomes has been through the
methodical modulation of ER stimulation. Findings from several studies have indicated a
role for specific ERs in memory performance. For instance, Rissman et al. (2002) found that
17βE2 impaired learning on the MM in ERβ KO mice compared to estrogen-treated WT
controls. Similarly, ERβ KO mice given 17βE2 were impaired on the Y-maze, exhibiting a
lower percentage of trials without an error than WTs and ERα KO mice receiving the same
treatment (Liu et al., 2008), further supporting the requirement of ERβ, and but not ERα, for
17βE2-induced spatial memory enhancements. Interestingly, other findings highlight the
importance of ERα in memory function. Foster et al. (2008) used a lentiviral vector to
restore ERα expression in adult Ovx, ERα KO mice, finding that increased ERα expression
in these animals enhanced spatial reference memory MM performance compared to that of
ERα KO controls. Studies using selective ER modulators (SERMs) as tools to evaluate the
impact of ER stimulation in young adult rats have also imparted mixed mnemonic effects.
For instance, there is disagreement regarding the impact of SERMs on object memory, with
some studies reporting that both propylpyrazole triol (PPT; ERα agonist) and
diarylpropionitrile (DPN; ERβ agonist) enhance performance, and others reporting that
either DPN or PPT, but not both, impart benefits (Frye et al., 2007; Jacome et al., 2010; Walf
et al., 2006). As well, findings on spatial memory tasks are also inconsistent. For example,
on the MM, DPN benefitted, while PPT failed to impact, spatial reference memory
performance (Rhodes and Frye, 2006). Conversely, PPT, DPN, and 17βE2 each enhanced
spatial working memory performance on the delayed match to position (DMP) task
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(Hammond et al., 2009). Among middle aged animals, PPT was associated with delayed
alternation impairments (Neese et al., 2010), even though Witty et al. (2012) found that
lentiviral-induced increases in hippocampal ERα expression benefitted radial arm maze
(RAM) working memory. Thus, the conflicting findings from these studies indicate that the
relationship between memory outcomes, ERs, ER ligand stimulation, and aging is complex
and requires further investigation to uncover clinical applications for ER-targeted
interventions.

6. Estrogen neuroprotection in brain injury
6.1. Estrogen and ischemia
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Afflicting nearly 795,000 people per year and associated with an annual total cost of 34
billion US dollars, stroke is the fifth leading cause of death and the leading cause of longterm disability in the United States. Similarly, stroke is the second-leading cause of death
worldwide, accounting for 11% of all deaths globally (Mozaffarian et al., 2015). Broadly
defined, stroke is a failure of the supply of oxygen and glucose to neurological tissues.
Accounting for 87% of stroke cases, ischemic stroke is caused by a blockage of a cerebral
artery, resulting in a loss of blood flow to the brain area supplied by that artery. The
phenotype of functional consequences can be diverse and the success of medical
recanalization interventions, such as chemical or mechanical endovascular therapy, are
important predictors of outcome. While surgeons typically employ a variety of tools to
physically disrupt or remove a clot, only one pharmacological option exists, recombinant
tissue plasminogen activator (tPA) (Mozaffarian et al., 2015; Rouchaud et al., 2011).
Although proven effective, the therapeutic window of tPA administration is exceptionally
short, due to the unacceptable increased risk of cerebral hemorrhage when given after that
time point (Gurman et al., 2015).
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6.1.1. Clinical studies—Sex differences in stroke are well documented. Although
younger women have a lower incidence of ischemic stroke than young adult men, the sex
difference shifts in older cohorts such that post-menopausal women have an equivalent or
higher incidence of stroke than their age-matched male counterparts (Reeves et al., 2008).
Women are affected by 40,000 more strokes annually than men, and represent approximately
56% of the 6.8 million stroke survivors in the United States. In addition, women are more
likely to be older at the time of first stroke and have a lower quality of life post-stroke than
their male counterparts, even after adjusting for other sex-specific variables (reviewed in
Bushnell and McCullough, 2014; Gibson, 2013). Indeed, results of the Framingham Heath
Study indicated that women were older at the time of stroke, have more comorbid disease at
time of stroke, and tend to have more severe strokes with worse outcomes (Petrea et al.,
2009). Of the many modifiable risk factors for stroke, including hypertension, history of
smoking, diabetic status, and physical activity, the primary non-modifiable risk factor for
stroke is increased age (Goldstein et al., 2011). Another non-modifiable risk factor for stroke
women is the onset of menopause. The stroke risk for women doubles approximately 10
years post-menopause. Menopause is also associated with an increased risk of the
modifiable risk factors listed above. Thus, large shifts in endogenous sex hormone levels, as
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well as prior use of estrogen-containing therapies, appear to be additional risk factors that
contribute to the female disadvantage in stroke risk (Lisabeth and Bushnell, 2012).
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Few clinical studies have examined the relationship between HT and stroke risk as a primary
outcome. Most clinical studies that have investigated the relationship between HT and
cardiovascular disease have focused on prevention of coronary heart disease rather than
stroke, and the overall evidence suggested no benefit of HT on stroke risk (Henderson and
Lobo, 2012; Paganini-Hill, 2001). The Women's Estrogen for Stroke Trial (WEST)
addressed stroke risk as the primary outcome in women with an intact uterus who had a
history of prior ischemic stroke or transient ischemic attack. Results from the WEST showed
that 17βE2-based HT had no effect on recurrent stroke after a 2.8 year follow-up (Viscoli et
al., 2001). In contrast, stroke risk was a secondary outcome in the WHI. The CEE-alone trial
of the WHI reported an increased risk (30%) of ischemic, but not hemorrhagic, stroke in
women who received CEE compared to placebo. This risk corresponds to an additional nine
cases of stroke per 10,000 person-years of HT use (Anderson et al., 2004; Henderson and
Lobo, 2012; Hendrix et al., 2006).
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Over the past 10 years since the termination of the WHI, several studies have re-examined
the major findings of the WHI to focus on the group of women in the WHI who were 50–59
years of age when they enrolled in the WHI, an age group that represents the time frame of
the menopausal transition. In one secondary analysis of the WHI, Roussow and colleagues
showed that the youngest group of women in the CEE arm of the study did not have an
increased risk of stroke (Rossouw et al., 2007). In the WHIMS-Y study, CEE administration
to women aged 50–55 at the beginning of the study sustained neither risk nor benefit to
cognitive function (Espeland et al., 2013). Current clinical guidelines recommend against the
use of any kind of HT for primary or secondary prevention of stroke. The guidelines also
emphasize that signifi-cant gaps persist in our understanding of the benefits and harms of
HT, particularly with younger women who are in the early peri-menopausal and postmenopausal periods (Bushnell and McCullough, 2014; Bushnell et al., 2014).
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6.1.2. Preclinical studies—The search for therapeutic agents to treat stroke remains
elusive. A greater appreciation of the gender biology of stroke in preclinical studies will
support this endeavor. In spite of the abundant epidemiological and physiological evidence
for a sexual dimorphism in stroke, most preclinical studies in stroke have been performed in
young, male rodents. We and others participated in a National Institute of Neurological
Disorders and Stroke-sponsored workshop in 2006 to summarize the research gaps
pertaining to stroke risk, with an emphasis on clinical and preclinical estrogen studies
(Bushnell et al., 2006). Following the early termination of the CEE arm of the WHI in 2004,
basic researchers sought to identify the reasons for the discrepancies between clinical and
preclinical studies (Anderson et al., 2004). While much experimental evidence from rodent
and non-human primate animal models of stroke, as well as in vitro models of ischemic
injury, overwhelmingly demonstrated that estrogenic compounds were neuroprotective, the
early termination of the estrogen-only arm of the WHI suggested otherwise.
Thus, it is critical that investigators identify the circumstances under which estrogen is
beneficial and when it is harmful. Two of the basic science research recommendations from
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this workshop pertained to sex steroids: (1) define which stimuli precipitate stroke events, as
well as the influence of sex steroids on these processes, and (2) delineate the mechanism by
which sex steroids and their mimetics act as neurovascular protectants in both stroke and
neurodegenerative disease models. Incorporating the physiological complexity of sex
steroids like estrogen into clinically-relevant, age-appropriate animal models of stroke is
paramount for implementation of a successful therapeutic agent for treatment of ischemic or
hemorrhagic stroke. We review critical variables in rodent models of stroke that have
contributed to our current perspectives on estrogen-mediated neuroprotection.
Representative studies are summarized in Table 2. Since many preclinical studies were
performed in rodents, this section will be limited to mouse and rat models of ischemic
stroke. The reader is referred to the following reviews for a discussion of animal models of
stroke in other species including nonhuman primates (Casals et al., 2011; Cook and
Tymianski, 2012) and estrogen action in animal models of ischemic stroke (Carswell et al.,
2010).
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One of the most important factors in preclinical stroke research is the selection of the
experimental model to ensure a reproducible injury. MCAO is the most common
experimental stroke model employed in rodents, using an intraluminal filament to occlude
the middle cerebral artery, thereby resulting in the loss of approximately 50–75% blood flow
to the cortex or striatum (Longa et al., 1989; Macrae, 2011). In pMCAO, the filament
remains lodged in the artery for the duration of experimental stroke (Bingham et al., 2005;
Dubal et al., 1998; Dubal et al., 2001; Perez et al., 2005a,b). Conversely, in a tMCAO model,
blood flow to the brain is blocked by the filament for a specific period of time, generally 30–
120 min, and is then removed. Filament removal allows re-entry of blood into the artery and
also results in reperfusion injury. Thus, pMCAO primarily assesses the effect of estrogen on
the injury due to loss of blood flow, while tMCAO assesses the effect of estrogen on injury
due to loss of blood flow and reperfusion injury. Fewer studies have employed global models
of tMCAO, which are characterized by brief (less than 20 min) periods that occlude blood
flow to both hemispheres (Horsburgh et al., 2002; Miller et al., 2005). An alternative MCAO
model employs injection of the vasoconstrictive peptide, ET-1; this method occludes blood
flow to 30–50% of normal and results in a delayed hypoperfusion (Biernaskie et al., 2001).
This model has been widely used to demonstrate the loss of estrogen's neuroprotective
effects in aged, reproductively senescent rats (Lewis et al., 2012; Selvamani and Sohrabji,
2010a,b). Similarly, Leon and colleagues (Leon et al., 2012) also showed a deleterious effect
of estrogen in aged rats using a tMCAO model coupled with the tPA during reperfusion. In
contrast, few laboratories have demonstrated a beneficial effect of estrogen in aged rats (Liu
et al., 2012). Occlusion via electrocoagulation has been used less frequently in experimental
ischemic stroke, with more neurodamaging effects of estrogen reported in this model than in
others (Bingham et al., 2005; Carswell et al., 2004; Gordon et al., 2005). The distinctions
among experimental stroke models, however subtle, are critically important when evaluating
the efficacy of estrogenic action in neuroprotection.
An additional critical difference between preclinical and clinical studies to assess estrogenmediated neuroprotection in ischemic stroke is the study endpoint or outcome. As shown in
Table 2, infarct volume or quantification of neuronal cell loss is the most common endpoint
in preclinical studies. In general, these studies have demonstrated that continuous treatment
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with 17βE2 reduces infarct volume in the cortex and to a lesser degree in the striatum, with
limited, if any protection in the hippocampus (Dubal et al., 1998; Dubal et al., 2001; Rusa et
al., 1999; Simpkins et al., 1997b). In contrast, the common endpoint for clinical studies is
functional or disease outcomes. Comparatively, a smaller number of preclinical studies have
employed acute functional endpoints or mortality as endpoints, whereas the benchmark for
therapeutic efficacy in humans is either survival or long-term recovery of motor function,
memory, or cognition. The effects of estrogen on functional outcome after ischemic stroke
are unclear and under-studied, as we identified a limited number of studies that reported any
effects of estrogen on either short-term (Strom et al., 2013; Wang et al., 1999; Zhang et al.,
1998) or long-term functional outcomes (Li et al., 2004). The appropriate design of
preclinical studies to uncover the mechanisms that determine whether estrogen promotes
long-term functional recovery following experimentally-induced stroke is essential for
elucidating the biological underpinnings of estrogen-mediated neuroprotection.
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We were one of the first laboratories to demonstrate estrogen-mediated neuroprotection in
rodents (Simpkins et al., 1997b), and many laboratories have expanded upon these findings
over the past twenty years. The age of animals, animal strain, estrogen treatment regimen,
and estrogen dose are all critical factors that have contributed to the discrepancies between
clinical and preclinical findings. overall, the majority of studies on estrogen and
neuroprotection have employed the tMCAO model while restricting blood flow at various
times within a 90 min time frame, with administration of varying doses and formulations of
estrogen either before injury, at the time of injury, prior to reperfusion, and after reperfusion.
It is critical that we elucidate, using clinically relevant models of ischemic stroke, the
circumstances under which estrogens are neuroprotective and when they are neurodamaging in ischemic stroke, as well as neurodegenerative disease. The Stroke therapy
Academic Industry Roundtable (STAIR) preclinical recommendations provide an excellent
foundation for sound experimental design coupled with transparent reporting of study
results. The recommendations of particular relevance to the study of estrogen-mediated
neuroprotection urge investigators to: (1) employ both acute and long-term histological and
functional endpoints and (2) use both permanent and transient occlusion models, and (3)
define the window of therapeutic efficacy (Fisher et al., 2009). We urge investigators to
implement these criteria in an effort to provide continued clarity to basic scientists,
clinicians, and, most importantly, the millions of women who desire to use HT to improve
their quality of life.
6.2. Estrogen and traumatic brain injury
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TBI is defined as an injury induced by an external force which results in altered brain
function or pathology, such as the presence of clinical symptoms of amnesia, loss of
consciousness, etc. (Menon et al., 2010). Although the mechanisms can be diverse (blunt
force, gun shot or other penetrative object, explosive blast, etc.), primary TBI is most
commonly associated with shearing and contusive damage to neural tissues due to an
external force and includes ischemic hypoxia, hematoma, edema, diffuse axonal injury and
contusion (reviewed in Maas et al., 2008). The initiation of several pathological cascades
results in a diffuse secondary TBI, the consequences of which may not be observable for
many days, weeks, or even years following the initial injury. Causes of secondary injury
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commonly include dysregulation of excitatory neurotransmitters, apoptosis and necrosis,
initiation of the inflammatory cascade, disruption of the BBB and cerebral blood flow
(CBF), altered energy metabolism, and free radical production. Thus, the pathophysiology of
TBI is associated with numerous detrimental neurobiological consequences.
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In addition to the devastating pathological processes associated with this condition, the
human impact of TBI is high. Each year, an estimated 1.7 million people sustain a TBI and
of those, approximately 53,000 will die (Coronado et al., 2011). Among the survivors, the
primary and secondary neuropathological alterations are associated with a variety of
detrimental consequences including cognitive decline, locomotor impairments, and
psychological problems, all of which can have profound negative impacts on daily living and
quality of life. It is known that TBI is associated with young adulthood, especially among
males, as it is major cause of death in this age group (Maas et al., 2008). As of 2005, there
were an estimated 3.17 million adults in the United States suffering from extended, and in
some cases life-long, disability associated with a TBI, making these insults extremely costburdensome on the healthcare system (Zaloshnja et al., 2008). In fact, total direct and
indirect estimated annual costs (including costs associated with missed work and lost
productivity) for the treatment of TBI have been estimated to be as high as 76.1 billion
dollars (Ma et al., 2014). Unfortunately, the incidence of TBI is rising, given that it is
becoming increasingly associated with aging as the large Baby Boomer population enters
senescence and become at higher risk for neurotrauma-inducing falls (Roozenbeek et al.,
2013). Thus, taken together, TBI represents an urgent medical need; characterizing risk
factors and developing interventions for these patients will become an increasingly
important direction for research.
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A significant risk factor for TBI, and therefore potential treatment option, may be genetic
sex and the associated circulating sex-specific hormones. Indeed, preclinical observations of
a female advantage in severity of TBI and functional recovery have been reported (Roof et
al., 1993; Wagner et al., 2002). Evidence suggests that shifts in the hormonal milieu are
associated with changes in risk/outcome. Protection from TBI in the rodent has been
reported in proestrous phase (Maghool et al., 2013) when estrogen levels are increasing,
although not all studies have replicated this effect (Wagner et al., 2004). Further supporting
this hypothesis is the finding that the protective female advantage on outcome measures,
such as a reduction of BBB permeability and cerebral edema, was attenuated or even
completely absent in Ovx-induced surgically hormone-deplete rats (Bramlett and Dietrich,
2001; Suzuki et al., 2004). Exogenous administration of 17βE2 either in the weeks
preceding insult or within minutes to hours after injury appears to ameliorate the detrimental
impacts of hormone deficiency (Khaksari et al., 2011; O'Connor et al., 2005; Roof and Hall,
2000), the effects of which have been shown to be mediated through a variety of
mechanisms including GPER1 and the classical genomic ERα and ERβ pathways as shown
via the use of SERMs (Asl et al., 2013; Day et al., 2013; Khaksari et al., 2013). Despite
these promising findings, not all studies report a beneficial effect of estrogen treatment
among female animals (Bruce-Keller et al., 2007; Lebesgue et al., 2006). For instance, in
Ovx mice, neither acute (10 μg/kg single intraperitoneal injection) nor chronic (180ug/ml
subcutaneous Silastic® capsule) 17βE2 given prior to undergoing a controlled cortical
impact TBI attenuated cortical and hippocampal cell loss nor impacted microglia reactivity
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(Bruce-Keller et al., 2007). Taken together, in general, findings from these studies support
the hypothesis that estrogens can exert neuroprotective benefits in TBI but further work is
needed to clarify the conditions in which these benefits will occur (Table 3).
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Similarly, the findings with regards to TBI at the bedside are also controversial. While some
studies note a protective effect of female sex (Berry et al., 2009; Groswasser et al., 1998),
many clinical reports have failed to find a sex-difference in post-TBI outcome (Coimbra et
al., 2003; Magnotti et al., 2008; Slewa-Younan et al., 2004) and others have suggested that
outcome among females was actually worse compared to male patients (Farace and Alves,
2000). For example, even after controlling for a variety of subject-level confounding factors,
female patients were found to have higher post-concussive symptoms at three months
following mild TBI (Bazarian et al., 2010). While the male-dominated adulthood sex
difference in TBI rate diminishes among elderly populations (Pentland et al., 1986), the
interactive effect of age appears to play an important role in outcomes for women.
Reproductive status is thought to mediate this effect. For instance, many of the studies in
which a detrimental effect of female sex on TBI was found were conducted in populations of
adult to middle-aged, and thus reproductively capable, women (Bazarian et al., 2010;
Coimbra et al., 2003). Farin et al. (2003) reported that women (ages 15–79) had a greater
frequency of brain swelling and intracranial hypertension than men. Yet when specific agegroups were compared, the detrimental effect was observed only in women younger than 51
while rates among aged men and women were similar. In addition, Berry et al. (2009) found
women in age brackets of 45–54 years and those older than 55 years of age (presumably
corresponding to the peri- and post-menopausal periods, respectively), but not women
younger than 45, had reduced mortality following moderate to severe TBI as compared to
males in this age-group. However, other studies have reported worse outcomes in older
populations of women (Gan et al., 2004; Pentland et al., 1986). Unfortunately, neither
reproductive status nor use of estrogen-containing treatments such OCs, HTs, etc., were
directly assessed (for example, by way of assessing circulating hormone levels, survey of
last menstrual period, or self-report of menopausal symptomology) in any of the
aforementioned studies and therefore, hormone status cannot be directly associated with
differences among these studies. Thus, the relationship between biological sex and outcome
in regards to TBI cannot be easily predicted by sex hormones and controversy as to
estrogen's neuroprotective role remains. Results of the RESCUE-TBI Phase II clinical trial
(NCT00973674; www.clinicaltrials.gov), which will evaluate the potential beneficial effects
of acute intravenous CEE treatment on short-term mortality and neurological outcomes
following TBI, will begin to clarify this important issue.
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7. Factors that influence the realization of neuroprotective effects of
estrogen
The evidence presented thus far suggests substantial support of estrogen as a neuroprotective
agent in several domains of brain function and injury. However, clinical and preclinical
findings of detrimental neurological effects following HT suggest that the story of estrogen's
impacts on the nervous system is not a simple one. Instead estrogen can be thought of as a
conditional neuroprotectant that, when administered, is associated with a multitude of
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beneficial impacts but whose biological actions are dictated by several modulating factors
that can substantially alter the realization of these beneficial effects. We have directly
addressed a set of these factors in the following subsections.
7.1. Etiology of hormone depletion
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Evidence suggests that the nature of the menopausal transition, either spontaneous/
transitional (also referred to as natural) or surgical, can influence cognitive outcomes during
aging. Studies in women have reported that cognitive performance is worse among women
who underwent oophorectomy at or before the time of spontaneous menopause (Nappi et al.,
1999; Rocca et al., 2007). This notion has also been described in work with aging rodents.
Indeed, the Bimonte-Nelson team has capitalized on a novel approach to hormone depletion
in animals (Acosta et al., 2009a, 2010). Characterized by Loretta Mayer et al. (2002), the
toxin vinylcyclohexene diepoxide (VCD) selectively depletes ovarian primordial and
primary follicles, resulting in a hormone environment associated with increased
gonadotropins, high circulating androstenedione, and very low levels of estrogens and
progesterone, a state that more similarly parallels the physiological milieu of a naturally
menopausal woman (Mayer et al., 2005). This transitional ‘menopause’ was associated with
cognitive deficits on tests of spatial working memory in middle-aged female rats (Acosta et
al., 2009a). Among these animals, higher levels of circulating androstenedione were
correlated with worse memory performance. This impairment was ameliorated by surgical
removal of the follicle-deplete ovary via Ovx. Animals that underwent transitional hormone
depletion followed by surgical removal of the depleted ovaries also outperformed animals
that underwent rapid hormone loss via Ovx surgery.
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As well, the effects of estrogen treatment may also differ depending on menopause etiology.
Findings from the WHI noted that different estrogen formulations given to women
depending upon whether their menopause was transitional (CEE + MPA) or surgical (CEE
alone) resulted in different effects on adverse outcomes such as stroke risk and probable
dementia (Manson et al., 2013). From a preclinical perspective, Acosta et al. (2010) noted
that CEE only benefitted memory performance in animals that had undergone Ovx; CEE
treatment among VCD-induced gradual hormone depleted animals actually impaired
memory performance among middle-age female rodents. Taken together, these findings
suggest that etiology of menopause can have important impacts on age-related changes in
cognition and response to injury; this factor should be considered in the context of
administration of exogenous estrogenic treatments.
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An additional important factor with regards to this issue is that patient age at the time of
hormone depletion also may play a role in health outcomes following menopause (Shuster et
al., 2010). Indeed, women with surgical menopause tend to be younger than transitional
menopausal women and cognitive detriments are associated with younger age at the time of
surgical hormone loss (Nappi et al., 1999; Rocca et al., 2007). Some studies have even failed
to detect differences in cognitive change among women undergoing hysterectomy with or
without bilateral oophorectomy when compared to similarly aged women undergoing
transitional menopause (Kok et al., 2006; Kritz-Silverstein and Barrett-Connor, 2002).
Additional support for the impact of age on hormone depletion effects stems from rodent
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work suggesting that Ovx is detrimental for memory in young adult animals, beneficial in
aged animals (Bimonte and Denenberg, 1999; Bimonte-Nelson et al., 2003), and transitions
from detrimental to beneficial during the reproductive senescence period (Engler et al.,
2007). Further work teasing apart the role for menopause etiology and age at which
menopause occurs is warranted.
7.2. Critical window for estrogenic intervention
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For many decades, converging evidence from observational and small, randomized trials
suggests that menopausal HT could protect against brain aging and cognitive decline
(Sherwin and Henry, 2008). Results of the large WHI were eagerly anticipated and expected
to validate the plethora of preclinical and clinical reports noting benefits with estrogencontaining HTs. Yet, surprisingly, the WHI reported an increased risk for ischemic stroke,
declines in global cognitive function, and a doubling in the risk of probable dementia among
women taking CEE + MPA (Rapp et al., 2003; Rossouw et al., 2002; Shumaker et al., 2003).
Among women taking unopposed CEE, there was an increased risk of stroke, a nonsignificant 49% increased risk of probable dementia, and suggestive evidence for impaired
global cognitive function (Anderson et al., 2004; Espeland et al., 2004; Shumaker et al.,
2004). Importantly, these women were at least 65 years of age at the time of evaluation for
cognitive outcomes. The publication of these controversial findings generated substantial
speculation as to the perplexing lack of neuroprotection. One prominent hypothesis was that
of the ‘critical window of opportunity’ for the realization of beneficial outcomes of
estrogenic intervention. Similarly, the ‘healthy cell’ theory proposed by Dr. Roberta Brinton
suggested that reductions in risk for age-related memory changes with estrogen-containing
treatments were more likely to be observed among younger, cognitively uncompromised,
healthy patients as opposed to those women with underlying age-related neuropathology
(Brinton, 2008). Indeed, analyses of WHI data stratified by age suggested that HT had fewer
adverse outcomes among younger menopausal women, who initiated treatment near the time
of menopause (Manson et al., 2013; Rossouw et al., 2002). Findings of a critical window of
opportunity for estrogenic intervention are mirrored in small observational and randomized
clinical studies in women (Maki, 2006). Indeed, among women who received bilateral
oophorectomy prior to age of spontaneous menopause, those that were treated with estrogen
therapy until age 50 did not show cognitive decline relative to a referent group of women
(Rocca et al., 2007). Similarly, Dumas et al. (2008) reported that estrogen is capable of
counteracting the memory impairing effect of cholinergic challenge but only when
administered near the time of menopause. As well, in women who initiated a short-term
regimen (2–3 years) of 17βE2-based HT near the time menopause, risk for cognitive decline
was reduced when performance was assessed at age 64 (Bagger et al., 2005). It is
noteworthy that this short-term treatment regimen was as effective at protecting cognitive
function as estrogen treatments lasting many years in duration. However, the estrogen
formulation used in the WHI was CEE, either alone or in combination with MPA. The WHI
Memory Study of Younger Women (WHIMS-Y) failed to note memory benefits with CEE
even when initiated near the time of menopause (Espeland et al., 2013). As well, the Kronos
Early Estrogen Prevention Cognitive and Affective Study (KEEPS) did not detect
differences on global cognitive outcomes (as measured by the Mini Mental Status Exam)
among women randomized to receive estrogen + progestin combination treatment (either
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oral CEE, or transdermal 17βE2, +micronized progesterone) as compared to placebo
(Gleason et al., 2015). Other factors, such as type of progestin included in the HT
formulation, differed between these studies; the impact of these other factors are hotly
debated and discussed in the sections detailed here as well as in several key reviews (Rocca
et al., 2014; Singh and Su, 2013). Nevertheless, results of an additional clinical trial
assessing the critical window of menopausal HT initiation, the Early Versus Late
Intervention Trial with Estradiol (ELITE; NCT00114517; www.clinicaltrials.gov) are
eagerly anticipated and will hopefully clarify this complicated hypothesis.
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Evidence from rodent literature also supports the notion that beneficial neuroprotective
effects of estrogen treatment will be realized if initiated near the time of hormone depletion
(Daniel, 2013; Maki, 2006). For instance, in an elegantly designed study of middle-aged
rats, 17βE2 was only protective against cognitive decline on the water RAM when initiated
at the time of, but not five months following, Ovx (Daniel et al., 2006). Other animal studies
support the existence of a critical period for estrogenic intervention following hormone
removal (Gibbs, 2000; Vedder et al., 2014), even if the duration of estrogen treatment is
short (Rodgers et al., 2010). This reduction in cognitive benefit following long delays
between hormone depletion and 17βE2 intervention is associated with an attenuated ability
of 17βE2 to increase hippocampal spine density, a failure to improve LTP, and brain region
specific changes in ERα expression (Bohacek and Daniel, 2009; McLaughlin et al., 2008;
Smith et al., 2010). Indeed, mounting evidence implicates age-related changes in expression
and/or function of ERα in the reduced neurological responsivity to estrogen and represents a
possible target for extending the therapeutic window of estrogen intervention (Foster, 2012).
Taken together, there is sufficient preclinical and clinical data to support the possible
existence of a critical window for HT initiation following hormone depletion. However, it is
as yet unclear whether a critical window exists for CEE, highlighting the possibility that
factors associated with the estrogenic formulation may also influence the neuroactive actions
of estrogen-containing HTs.
7.3. Estrogen type
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7.3.1. Conjugated equine estrogen therapy—The majority of studies reporting
beneficial effects of estrogen within the context of cognition, stroke, and TBI utilized the
most potent circulating estrogen, 17βE2 (Maki, 2012; Sherwin and Henry, 2008). Yet,
17βE2 is not a prevalent component of the most common menopausal HTs used by women.
CEE, a purified pregnant mare urine complex of estrogens first developed by Wyeth, is the
most widely used estrogen-based menopausal HT in North America (Hersh et al., 2004).
Although primarily composed of E1 sulfate and containing only trace amounts of 17βE2,
CEE is a mixture of at least 10 estrogen sulfates, many of which are unique to horses and
have yet to be evaluated for their neuroprotective impacts in a human or rodent model (Kuhl,
2005). After metabolism, the biologically active hormones in circulation are primarily E1
and the more potent 17βE2, as well as equine-specific estrogens such as equilin and delta8,9dehydroestrone (Bhavnani, 2003; Kuhl, 2005). Despite CEE being an effective treatment for
relieving the negative vasomotor symptoms and vaginal atrophy of menopause (Freedman,
2002), clinical and preclinical findings of CEE's neuroprotective effects are inconclusive.
Model-specific effects have been noted. Among women, in an excellent review by Sherwin
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and Henry (2008), the authors note that studies in which menopausal HT improved cognitive
performance measures utilized 17βE2, while CEE was the principal HT used by women in
those studies reporting null or negative effects. Cell culture models suggest that CEE can be
neuroprotective. Specifically, CEE enhances neuronal growth and increases neuronal
survival after experimentally-induced insult in vitro (Brinton et al., 2000; Diaz Brinton et al.,
2000). The results from a limited number of preclinical studies assessing the effects of CEE
in experimental stroke in vivo suggest that CEE may, but not always, reduce infarct volume
(Littleton-Kearney et al., 2005; Rusa et al., 1999). One study noted no differences in poststroke lesion volume, and thus no protection, among Ovx female rats given an acute CEE
injection 30 min before MCAO (Rusa et al., 1999). However, it is worth noting that these
studies were carried out in young, healthy rodents. CEE has also been shown to impact
cognition in the middle-aged Ovx rat. CEE administered subcutaneously via an acute
injection (Walf and Frye, 2008), via chronic cyclical injections (Acosta et al., 2009a,b), or at
higher doses administered via continuous release from osmotic pumps (Engler-Chiurazzi et
al., 2011), enhances object memory and spatial navigation memory. Yet, detrimental effects
have also been reported. Indeed, in young adult Ovx rats, although daily injections of CEE
increased hippocampal neurogenesis, this treatment was associated with memory
impairments on the RAM (Barha and Galea, 2013). In this same study, CEE also increased
numbers of new neurons; this increase correlated with worse maze performance among
treated groups. Further, we have reported that CEE dose-dependently impaired working
memory performance in middle-aged, Ovx rats, an effect possibly related to the ratio of
circulating estrogens (Engler-Chiurazzi et al., 2011). Taken together, the findings regarding
the neurobiological impact of CEE are inconsistent across several experimental models.
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7.3.2. Feminizing estrogenic components of conjugated equine estrogen—
Feminizing estrogen components of CEE appear to exert their own neuroactive, yet not
always neuroprotective, effects. E1 sulfate is the principle component of CEE and following
treatment with CEE to peri- and post-menopausal women, and middle-aged, Ovx rats,
circulating levels of E1 increase (Acosta et al., 2009a,b; Yasui et al., 1999). In addition, prior
to menopause, endogenous E1 circulates in approximately a 1:1 ratio with 17βE2 (Rannevik
et al., 1995). However, during the menopausal transition, levels of 17βE2 decline to a greater
extent than do levels of E1, changing the circulating E1 to 17βE2 ratio to 2:1 (Rannevik et
al., 1995). Thus, this large change in the circulating ratio of E1 to 17βE2 both due to aging
and to HTs may have a significant impact on cognitive ability and neuroprotection and
makes quantifying the neurobiological impact of this estrogen clinically relevant. In vitro
work suggests protective effects with E1 treatment against cellular insult (Zhao and Brinton,
2006). However, for most measures in which other estrogenic CEE components (e.g., equilin
and delta8,9-dehydroestrone) were neuroprotective, E1 was less effective (Brinton et al.,
1997; Zhao and Brinton, 2006). In an in vivo behaving rodent, detrimental effects are
observed. Indeed, unlike 17βE2 or another CEE component, delta8,9-dehydroestrone, E1
dose-dependently failed to impact, and at some doses even impaired, aversive memory in the
contextual fear conditioning task and spatial working memory among adult and middle-aged
Ovx rats (Barha et al., 2009a; Engler-Chiurazzi et al., 2012; Talboom et al., 2010). Further,
while chronic 17βE2 increased basal forebrain ChAT-immunoreactive neurons and number
of bromodeoxyuridine (BrdU)-labeled neurons in the DG, substrates underlying memory
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performance, chronic E1 does not impart these same changes (Engler-Chiurazzi et al., 2012;
McClure et al., 2013). Thus, taken together, evidence suggests that E1 is not an optimal
neuroprotectant nor an ideal component of menopausal HT and highlights that the type of
estrogen contained in a HT formulation should be of primary consideration in the design of
future treatments.

Author Manuscript

7.3.3. Non-feminizing estrogens—The use of non-feminizing estrogens holds promise
as an alternative for the development of novel HTs (Petrone et al., 2014). 17 alpha-estradiol
(17αE2) binds to each ER with a substantially lower affinity than does 17βE2 (Kuiper et al.,
1997) and likely does not stimulate peripheral reproductive tissues. In vitro, 17αE2 is as
protective against the toxic effects of serum deprivation (Green et al., 1997) and oxidative
stress as 17βE2 (Green et al., 2001). Further, 17αE2 is synthesized in the brain and thought
to underlie the rapid membrane receptor-mediated actions of estrogen (Toran-Allerand et al.,
2005). 17αE2 protects against ischemic insult (Simpkins et al., 1997b), reduces Alzheimer's
Disease-associated β-amyloid levels in transgenic mice (Levin-Allerhand et al., 2002), and
improves cognitive outcomes including object, reference, and context fear memory (Barha et
al., 2009a; Inagaki et al., 2010; Luine et al., 2003; Rhodes and Frye, 2006). These enhancing
effects may be mediated by its demonstrated ability to increase DG cell proliferation (Barha
et al., 2009b) and/or to increase hippocampal spine density (MacLusky et al., 2005). In some
disease states, 17αE2 may even be more neuroprotective than its stereoisomer. Using a
model of neonatal brain damage, McClean and Nuñez (2008) note that 17αE2, but not
17βE2, attenuated memory impairments and reductions in hippocampal cell volume
following muscimol treatment. Thus, the findings regarding beneficial effects of 17αE2
suggest that feminizing ligand-ER interations may not be a pre-requisite for estrogen
neuroprotection.
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More broadly, the identification of the molecular characteristics necessary for the
neuroprotective effects of 17βE2 represent an important strategy in the optimization of
current and future HT options. Indeed, it is the phenolic structure of the estrogen molecule
that is essential for the realization of protection against oxidative stress and serum
deprivation (Behl et al., 1997; Green et al., 1997). Modifications to the molecular structure
of endogenous parent estrogens, E1 or 17βE2, to minimize the detrimental stimulatory
estrogenic actions in uterus and breast while simultaneously imparting neuroprotective
effects have yielded promising results (Yi et al., 2011). In general, A-ring modifications such
as the addition of bulky alkyl groups at the 2- and 4-carbon positions can enhance
neuroprotection following a variety of in vitro insults (Perez et al., 2005a,b) as well as
following cerebral ischemia in vivo (Perez et al., 2005a). Importantly, in these models, such
modifications are more potent neuroprotectants than the parent 17βE2 molecule yet also
substantially reduce binding to and activity at the ER. These findings suggest that these
novel estrogen analogs impart their neuroprotective effects via their anti-oxidant activity or
other mechanisms independent of the classical nuclear cascade (Perez et al., 2005b),
representing a novel and effective therapeutic intervention approach for the treatment of
menopausal symptoms and the prevention of injury-induced neuropathology.
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In addition to the type of estrogen formulation selected, factors associated with the way in
which the estrogenic treatment is administered are important clinical considerations;
variations in estrogen administration can have meaningful impacts on the realization of
neuroprotection. Indeed, several studies suggest that there is an optimal dose range for
cognitive outcomes in rodents (Barha et al., 2009a; Holmes et al., 2002; Inagaki et al., 2010;
MacLusky et al., 2005). As well, converging evidence suggests that the mode of treatment
regimen (acute/cyclic versus chronic/continuous) can influence the effectiveness of the
estrogen formulation. For instance, acute or intermittent injection regimens of 17βE2 impart
neuroprotection in models of TBI and stroke and can enhance memory on multiple
behavioral tasks (Bimonte-Nelson et al., 2006; Gresack and Frick, 2004; Luine et al., 2003;
O’Connor et al., 2005; Roof and Hall, 2000). However, as shown in Tables 1–3, studies
utilizing chronic treatment via continuous administration regimens do not always report
beneficial effects. Differences in ER expression, with cyclic estrogen treatment facilitating
ER recycling, and continuous estrogen treatment down-regulating ERs, indicate divergent
neural mechanisms of action for distinct modes of treatment administration that likely
impact the neurobiological effects of estrogens (Blaustein, 1993; Brown et al., 1996; Kassis
and Gorski, 1981; Rosser et al., 1993). However, differences in methodological approach,
such as injury model used, timing of estrogen treatment relative to assessment, or outcomes/
cognitive tests evaluated, could also account for lack of consistent beneficial estrogenic
effects between studies. More work to clarify the unique impact of each of these factors is
warranted.
7.5. Genetic sex
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The recent change in National Institutes of Health funding guidelines to require the
consideration as sex as a biological variable in new grant proposals highlights the
importance of systematic investigation of sex differences in response to neuroprotective
interventions. As such, a brief discussion of the actions of estrogens in the male is
warranted. As has been shown among females, 17βE2 treatment in males can impact
cognitive outcomes. For instance, continuous administration of 17βE2 enhanced delayed
memory retention among adult and aged male rats (Luine and Rodriguez, 1994) and acute
post-training 17βE2 injected directly into hippocampus enhanced reference memory MM
performance (Packard et al., 1996). The protective effects of estrogen treatment in the
context of brain injury also extend to males. Indeed, although castration of adult male rats
did not alter stroke injury following reversible MCAO, treatment of 17βE2 to castrated
animals reduced cortical and caudate infarct volume (Toung et al., 1998 but see Hawk et al.,
1998). As well, some of the earliest reports of estrogen use in rodent models of TBI
suggested that 17βE2 could attenuate infract size and improve CBF of male animals
(Emerson et al., 1993; O'Connor et al., 2005; Roof and Hall, 2000). Other estrogens and
estrogen formulations also show promising neuroprotective effects in males. A single
intravenous injection of CEE during reperfusion following MCAO reduced infarct volume
(Toung et al., 1998) and increased CBF recovery (McCullough et al., 2001). Further, both
CEE (Chen et al., 2009; Soustiel et al., 2005) and E1 (Gatson et al., 2012) significantly
reduced insult-induced lesion size and apoptosis following TBI in young adult male rats. As
of yet, there is a paucity of reports examining the neuroprotective effects of CEE or E1 in
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both males and females following stroke or TBI. Investigations regarding the impacts of
these unique estrogen types and formulations in both sexes are crucial to attaining a
comprehensive understanding of the utility of estrogen as a neuroprotective agent (see
Section 7.3).

8. Summary, conclusions, and future directions: from testes to today
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As has been discussed in the preceding sections, there is ample empirical evidence to
support the notion that sex hormones impact body and brain. As was shown in Berthold's
caponized roosters, the loss of these hormones can have dramatic behavioral alterations.
Since that time, the knowledge regarding the intricacies of reproductive control by the
endocrine system and the interations between this system and other body structures,
including the brain, has advanced substantially, leading to the growth of the women's health
field and to the development of therapeutic interventions to modulate the physiological
effects of shifts in hormonal milieu, such as those occurring during the menopausal
transition. Some of these interventions have numerous beneficial impacts not only on
symptomatic relief but may also provide protection against cognitive aging and brain
trauma. Yet, sufficient evidence suggesting null or even detrimental neurological effects of
some estrogen-containing formulations has led to uncertainty among basic scientists,
clinicians, and patients regarding the use of estrogen-containing treatments for neuroprotection and rescue of the damaged brain.
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Deciphering the complexities of this important public health issue has proved a significant
challenge for the field given the diversity of models, formulations, administration regimens,
and outcome measures used to evaluate estrogenic action. Converging evidence presented
here has identified a number of factors that impact the realization of beneficial effects of
estrogenic treatments (Fig. 1). These factors can be divided into three broad categories that
include: (1) subject factors, (2) treatment administration factors, and (3) treatment
formulation factors. It is noteworthy that none of these factors can be considered in isolation
as they likely interact to exacERβate or attenuate the actions of each other. As well,
consistency and specificity of biological outcome measures across studies are crucial for a
cohesive understanding of the actions of a particular estrogen-containing treatment. For
example, administration of CEE, a formulation with mixed findings regarding its impact on
memory, may not be sufficient to alter cognitive performance of a healthy perimenopausal
woman. However, detrimental cognitive impacts of CEE could be compounded when it is
administered to an elderly woman many years removed from spontaneous menopause.
Further, these detriments may be especially prominent if the CEE treatment were
administered chronically via non-optimal route or at an inappropriate dosage. Finally, these
impacts may not be global but instead specific to certain performance domains. Thus, the
actions of estrogen within the normal, aging, and injured brain are diverse, conditional, and
contingent on a number of factors. Developing criteria standards for desired beneficial
peripheral and neuroprotective outcomes while simultaneously avoiding detrimental
stimulatory actions among unique patient populations will be an important future direction
for the optimization of estrogen treatments within the context of cognitive aging and brain
injury.
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Fig. 1.

Estrogen as a conditional neuroprotectant. Estrogen acts as a neuroprotectant whose
biological actions are modulated by subject factors, treatment administration factors, and
treatment formulation factors.
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Table 1
a

Author Manuscript

Effects of exogenous estrogen treatment on cognition in ovariectomized female rodents.
Estrogen

Reference

Age (months)

Treatment regimen

Dose

Cognitive outcome

Cognitive effect

17βE2

Luine et al.,
2003

2

Acute injection

15 μg/kg

OR, OP

Enhanced

Daniel and
Dohanich,
2001

2

Acute injection

10 μg

RAM

Enhanced

Gresack and
Frick, 2004

6

Cyclic daily injections

0.1 mg/kg

Water RAM, OR

No impact

0.2 mg/kg

Water RAM, OR

Enhanced

c

Pellet

2-way AA, MM

Enhanced

c

10 mm capsule
(0.025 in ID)

Water RAM

No impact

2 × 10mm capsules
(0.025 in ID)

Water RAM

Enhanced

c

3 mm capsule (0.058
in ID)

DMP + scopolamine
challenge

Enhanced

Continuous

c

5 mm capsule (0.058
in ID)

RAM

Enhanced

Simpkins et
al., 1997a,b
Bimonte and
Denenberg,
1999

b

Adult
2

Continuous
Continuous

Author Manuscript

Gibbs, 1999

5

Daniel et al.,
1997

2

Talboom et
al., 2008

4

Continuous

0.25 mg; pellet

MM

Enhanced

16

Continuous

0.25 mg; pellet

MM

Enhanced

24

c
Continuous

0.25 mg; pellet

MM

Minor enhancement

5 mm capsule (0.058
in ID) at time of Ovx

RAM

Enhanced

5 mm capsule (0.058
in ID)

RAM

No impact

10μg/0.10ml

RAM

Impaired

20 μg/0.10ml

RAM

No impact

0.625 mg/kg

OR

Enhanced

10 μg/day

MM, DMS

Enhanced

20μg/day

MM, DMS

Enhanced

30μg/day

MM, DMS

Enhanced

12 μg/day; pump

MM, DMS

Impaired

24 μg/day; pump

Water RAM, DMS

Enhanced

36 μg/day; pump

Water RAM, DMS

Enhanced

0.30 μg/.10ml

Contextual
Conditioned Fear
Response

No impact

1 μg/.10ml

Contextual
Conditioned Fear
Response

Impaired

Daniel et al.,
2006

Continuous

c

12

Continuous

Author Manuscript

5 months post-Ovx
CEE

Barha and
Galea, 2013

Adult

Walf and
Frye, 2008

13

Acosta et al.,
2009a,b

13

EnglerChiurazzi et
al., 2011

Author Manuscript

E1

b

Barha et al.,
2009a,b

Cyclic daily injections

Acute injection

d

Cyclic daily injections

13

Continuous

b

Adult

Acute injection
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Estrogen

Reference

Author Manuscript

McClure et
al., 2013
EnglerChiurazzi et
al., 2012

17αE2

Luine et al.,
2003
Barha et al.
2009

Page 55

Age (months)

b

Adult
13

2

b

Adult

Treatment regimen

Dose

Cognitive outcome

Cognitive effect

10 μg/0.1 ml

Contextual
Conditioned Fear
Response

No impact

Cyclic daily injections

10 μg/0.1 ml

MM

Impaired

Continuous

2.6 μg/day; pump

DMS

No impact

4.0 μg/day; pump

DMS

No impact

Author Manuscript

8.0μg/day; pump

DMS

Impaired

Acute injection

15 μg/kg

OR, OP

Enhanced

Acute injection

0.30 μg/.10ml

Contextual
conditioned fear
response

Enhanced

1 μg/.10ml

Contextual
conditioned fear
response

Impaired

10 μg/0.1 ml

Contextual
conditioned fear
response

Impaired

Note: All outcomes described are compared to Ovx animals given vehicle.
a

See list of abbreviations for tests used.

b

Weights, but not ages, were provided.

c

Subcutaneous pellets or Silastic capsules were used. Doses listed, when provided in each reference, were based on approximate circulating
estrogen levels after release. ID refers to inner diameter.

d

Injection regimen consisted of two days of treatment followed by two days off.
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Author Manuscript
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Author Manuscript

Author Manuscript

Author Manuscript

Simpkins et al.,
1997a,b

17βE2

b

tMCAO 40min + 24 h
reperfusion
tMCAO 30 min + 72 h
reperfusion

pMCAO
pMCAO, 24h

b
b

b
b

Wang et al., 1999

Yang et al., 2000

Dubal et al.,
2001
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Transient global ischemia
10 min

21 days
3

6-7

Miller et al.,
2005

Bingham et al.,
2005

Selvamani and
Sohrabji,
2010a,b

Endothelin-induced MCAO
(ET-1), 7 days

pMCAO, electrocoagulation
24 h

pMCAO

Gordon et al.,
2005

tMCAO 90 min + 2-6wk
reperfusion

Li et al., 2004

2-3

Transient global ischemia,
17 min

Horsburgh et al.,
2002

Adult

Adult

Adult

Adult

Zhang et al.,
1998

pMCAO, 24h

tMCAO 40 min + 24 h
reperfusion

Injury mechanism

tMCAO 120min + 22 h
reperfusion

Adult

Adult

Age
(mo)

Adult

Rusa et al., 1999

Dubal et al.,
1998

Reference

Estrogen

Pellet

Continuous

Continuous

Continuous

Infarct volume Ctx, Str

Neuronal perikaryal damage

0.25 mg; pellet
1.0 mg; pellet

Neuronal perikaryal damage

Neuronal number Hippo

Infarct volume

Infarct volume

Infarct volume

0.025 mg; pellet

Pellet

250 μg; capsule

Continuous

Continuous

25 μg; capsule

Cylinder Test

Infarct volume
180 μg/ml; capsule

Pellet

Infarct volume Ctx, Str, Hippo

Region-dependent decrease

Increased

Increased

Increased

Increased

Increased

Increased

Improved

Decreased

Decreased
Decreased

Region-dependent decrease

Decrease, up to 4 h post-injury

Decreased

Neurological score
Infarct volume

Decreased

Decreased
Decreased

Decreased
No impact

Region-dependent decrease

Region-dependent decrease

Decreased

Effect

Percent cell loss Str, Hippo

Infarct volume Ctx
Mortality

Infarct volume Ctx
Infarct volume Ctx

Infarct volume Ctx, Str

Infarct volume Ctx, Str

Infarct volume

Stroke
outcome

Infarct volume
Infarct volume

a

25 μg; capsule
250 μg; capsule

180 μg/ml; capsule

100 μg/kg

0.1 mg/kg

1 mg/kg

25 μg; pellet
100 μg; pellet

1 mg/ml; capsule

180 μg/ml; capsule

1 mg/kg

Dose

Continuous

Continuous

Continuous

Continuous

Acute injection 0.5-4 h postinjury

Cyclic daily injections 2 wks
pre-injury

Acute injection 40 min postinjury

Continuous

Continuous

Acute injection 24 h pre-injury

Treatment
regimen

Effects of exogenous estrogen treatment on ischemic stroke outcome in ovariectomized female rodents.
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Table 2
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Author Manuscript
b

tMCAO 60 min+ 24 h
reperfusion

b

Adult

tMCAO 60 min+ 24 h
reperfusion

tMCAO 40 min + 24 h
reperfusion

b

Adult

Adult

tMCAO 120min + 22 h
reperfusion

tMCAO 120 min + 22 h
reperfusion

Acute injection 2 h pre-injury

Acute injection 2 h pre-injury

Acute injection 24 h pre-injury

Consumed from diet 2 mo preinjury

Acute injection 1 h pre-injury

Acute injection, pre-injury

Continuous
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ZYC3 refers to 2-adamantyl-estra-1,3,5(10)-trien-3-ol-17-one.

c

Weights, but not ages, were provided.

b

See list of abbreviation for brain regions and stroke models.

a

100 μg/kg

100 μg/kg

1 mg/kg; capsule

0.625 mg/day

1 mg/kg

Infarct volume

Infarct volume

Infarct volume

Infarct volume Ctx, Subctx

Infarct volume Ctx

Infarct volume

Functional recovery

50,000 μg/ml; capsule
100 μg/kg

Infarct volume

50,000 μg/ml; capsule

Decreased

Decreased

Decreased

Decreased

None

Decreased

No impact

No impact

No impact
No impact

No impact

Functional recovery
Infarct volume
Functional recovery

Increased

No impact

Decreased

Increased

Effect

Infract volume Ctx, Str

Infarct volume Ctx, Str

Infarct volume Ctx, Str

Infarct volume Ctx, Str

Stroke
outcome

180 μg/ml; capsule
180 μg/ml; capsule

1.5 mg; pellet

180 μg/ml; pellet

Acute
Continuous

180 μg/ml; pellet

1.0 mg; pellet

Dose

Continuous

Continuous

Treatment
regimen

Note: All outcomes described are compared to Ovx, injured animals given vehicle.

Ent-E2

Green et al.,
2001

Liu et al., 2002

c

ZYC3

Simpkins et al.,
1997a,b

2-3

LittletonKearney et al.,
2005

17αE2

Adult

Rusa et al., 1999

CEE

pMCAO

b

Adult

Perez et al.,
2005a,b

E1

tMCAO 60 min+ 72 h
reperfusion

tMCAO + tPA reperfusion

tMCAO 90 min +
reperfusion

b

Adult

18

Leon et al., 2012

Strom et al.,
2013

17-22

Endothelin-induced MCAO
(ET-1), 7 days

10-12

Liu et al., 2012

Injury mechanism

Author Manuscript
Age
(mo)

Author Manuscript

Reference

Author Manuscript

Estrogen
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Table 3

Author Manuscript

Effects of exogenous estrogen treatment on traumatic brain injury in ovariectomized female rodents.
Estrogen

Reference

Age (months)

17βE2

Roof and
Hall, 2000

Adult

a

Injury mechanism

Treatment regimen

Dose

Outcome

Effect

Impact acceleration
(500g from 1.5 m)

Cyclic daily injections

0.1 mg/kg

Cortical blood flow

Protection

Author Manuscript

O'Connor
et al.,
2005

2

Impact acceleration
(450g from 2m)

Acute injection

33.3 μg/kg

Cerebral edema
Blood-brain barrier
permeability

Protection
Protection

Roof et
al., 1993

3

Controlled cortical
impact (2.25 m/s, 2
mm depth)

Continuous

5 mm capsule

Cerebral edema

No impact

BruceKeller et
al., 2007

2-3

Controlled cortical
impact (3.5 m/s, 1
mm depth)

Acute injection

10 μg/kg

Cortical tissue
sparing
Hippocampal
neuronal injury

No impact
No impact

Microglial activation

No impact

2-3

Controlled cortical
impact (3.5 m/s, 1
mm depth)

Continuous

10 mm

Cortical tissue
sparing
Hippocampal
neuronal injury

No impact
No impact

Microglial activation

No impact

Adult

Controlled cortical
impact (3.0 m/s,
1.2 mm depth)

Acute injection

100 μg/kg

Cortical apoptosis

Protection

Lateral fluid
percussion (2.4-2.9
atm pulse)

Continuous

0.1 mg; pellet

Hippocampal
apoptosis
Hippocampal DNA
damage

No impact
No impact

MWM

No impact

Mortality

Worsened

Petrone et
al., 2014
Lebesgue
et al.,
2006

a

Adult

Note: All outcomes described are compared to Ovx, injured animals given vehicle.
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a

Weights, but not ages, were provided.
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